Aripiprazole Tablet
Product Images NDC 13668-216

24 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 13668-216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description Image (Structure)

Description Image (Structure)
Chemical structure diagram of aripiprazole, depicting its molecular framework with labeled atoms and bonds, including two chlorine atoms, a piperazine ring, and a quinolinone moiety.*
FDA Label Image

Image 1 (Figure 1)

Image 1 (Figure 1)
A figure titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics' depicting the fold change and 90% confidence intervals for aripiprazole exposure (AUC and Cmax) due to co-administration with various inhibitors, inducers, and other drugs. The x-axis shows the change relative to reference (without interacting drug) ranging from 0.0 to 3.0. Drugs include CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, valproate, lithium, and lorazepam.*
FDA Label Image

Image 2 (Figure 2)

Image 2 (Figure 2)
A chart titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold changes and 90% confidence intervals for the AUC and Cmax of dehydro-aripiprazole when co-administered with various drugs. It includes CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam. The x-axis represents fold change relative to reference (no interacting drug).*
FDA Label Image

Image 3 (Figure 3)

Image 3 (Figure 3)
A pharmacokinetic chart titled 'Effect of Aripiprazole on Other Drugs' showing fold changes and 90% confidence intervals for various drugs, including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents fold change relative to reference without interacting drug, ranging from 0.5 to 3.0, with data points indicating aripiprazole's effect on AUC and Cmax values of these drugs.*
FDA Label Image

Image 4 (Figure 4)

Image 4 (Figure 4)
A scatter plot with error bars illustrating the effect of intrinsic factors on aripiprazole pharmacokinetics. The x-axis represents change relative to reference (0.5 to 3.0), and the y-axis lists special populations and conditions such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and renal impairment. The chart compares AUC and Cmax values for each category, showing fold changes with 90% confidence intervals.*
FDA Label Image

Image 5 (Figure 5)

Image 5 (Figure 5)
A pharmacokinetic chart showing the effect of intrinsic factors on dehydro-aripiprazole pharmacokinetics. It compares fold changes and 90% confidence intervals in AUC and Cmax for variables including CYP2D6 metabolizer status, gender, age groups, and levels of hepatic and renal impairment, with changes relative to a reference baseline.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse over time in days from randomization for a schizophrenia study. The graph compares aripiprazole and placebo groups, with the y-axis representing the proportion with relapse and the x-axis showing days from randomization. The number of subjects at risk is listed below the x-axis for each time point.*
FDA Label Image

7 (Figure 7)

7 (Figure 7)
Kaplan-Meier curve depicting cumulative proportion of patients with relapse over days from randomization in a bipolar study, comparing aripiprazole and placebo. The y-axis shows proportion with relapse, and the x-axis shows days with subject counts at risk for each group below.*
FDA Label Image

8 (Figure 8)

8 (Figure 8)
Kaplan-Meier curve showing the cumulative proportion of patients with relapse to any mood event over 364 days in a bipolar disorder study. The graph compares two groups: patients treated with aripiprazole and patients given a placebo, illustrating the proportion with relapse on the vertical axis and days from randomization on the horizontal axis.*
FDA Label Image

9 (Figure 9)

9 (Figure 9)
A line graph showing the least squares mean change from baseline in YGTSS Total Tic Score over eight weeks of treatment. It compares three groups: aripiprazole at low dose, aripiprazole at high dose, and placebo. The vertical axis represents the mean change in score, and the horizontal axis represents weeks of treatment, demonstrating decreasing tic scores over time, with the highest decrease in the high-dose aripiprazole group.*
FDA Label Image
FDA Label Image
FDA Label Image

2mg (2mg Indrad)

2mg (2mg Indrad)
Label for Aripiprazole Tablets, USP 2 mg oral tablets, manufactured by Torrent Pharmaceuticals Limited. The label indicates a quantity of 30 tablets, includes storage instructions, dosage note, a pharmacist dispensing directive, and a barcode. The label also provides manufacturer information and a website for the medication guide.*
FDA Label Image

2mg (2mg Dahej)

2mg (2mg Dahej)
Label for Aripiprazole Tablets, USP 2 mg oral tablets, containing 30 tablets per container. Manufactured by Torrent Pharmaceuticals Limited. The label includes storage instructions, dosage guidance referencing accompanying prescribing information, and a QR code. The product is marked for prescription use only.*
FDA Label Image

5mg (5mg Indrad)

5mg (5mg Indrad)
Label for Aripiprazole Tablets, USP 5 mg, containing 30 tablets. The label includes storage instructions, dispensing warnings, and notes that the medication guide must be provided to the patient. Manufactured by Torrent Pharmaceuticals Limited. The label displays the NDC number 13668-217-30 and indicates prescription use (Rx only).*
FDA Label Image

5mg (5mg Dahej)

5mg (5mg Dahej)
Label for Aripiprazole Tablets, USP 5 mg, oral tablets in a package of 30 tablets. The label includes dosage strength and instructions to dispense the accompanying Medication Guide. Manufactured by Torrent Pharmaceuticals Limited. The label features storage instructions and a barcode.*
FDA Label Image

10mg (10mg Indrad)

10mg (10mg Indrad)
Label for Aripiprazole Tablets, USP 10 mg, in a bottle of 30 tablets. The label includes storage instructions (20º to 25ºC), a child-resistant dispensing note, and directs to a medication guide URL. Manufactured by Torrent Pharmaceuticals Limited. The label features the Torrent Pharma logo and indicates Rx only.*
FDA Label Image

10mg (10mg Dahej)

10mg (10mg Dahej)
The image shows a label for Aripiprazole Tablets 10 mg, containing 30 tablets. The label includes storage instructions, prescribing information notice, and a Medication Guide URL. It indicates the product is manufactured by Torrent Pharmaceuticals Limited and requires pharmacist dispensing with prescription only (Rx only). The National Drug Code (NDC) is 13668-218-30.*
FDA Label Image

15mg (15mg Indrad)

15mg (15mg Indrad)
Label for Aripiprazole Tablets, USP 15 mg, manufactured by Torrent Pharmaceuticals Limited. The label indicates the package contains 30 tablets with storage instructions between 20° to 25°C and child-resistant packaging. It includes directions to dispense accompanying medication guide, and displays barcodes and the NDC 13668-219-30.*
FDA Label Image

15mg (15mg Dahej)

15mg (15mg Dahej)
Label for Aripiprazole Tablets USP 15 mg oral tablets, supplied in a container of 30 tablets. The label includes storage instructions, dosage information directing to accompanying prescribing information, and the labeler Torrent Pharmaceuticals Limited. It also features an NDC number 13668-219-30 and a barcode.*
FDA Label Image

20mg (20mg Indrad)

20mg (20mg Indrad)
Label for Aripiprazole Tablets USP 20 mg by Torrent Pharmaceuticals Limited. The label indicates a package of 30 tablets with the NDC number 13668-220-30. It includes storage instructions, a medication guide note, pharmacist dispensing instructions, and manufacturer details. The label is primarily white and blue with the Torrent Pharma logo.*
FDA Label Image

20mg (20mg Dahej)

20mg (20mg Dahej)
Label for Aripiprazole Tablets USP 20 mg by Torrent Pharmaceuticals Limited. Contains 30 oral tablets with dosing instructions referencing the medication guide. Storage conditions and packaging info are included, along with a barcode and NDC 13668-220-30.*
FDA Label Image

30mg (30mg Indrad)

30mg (30mg Indrad)
Label for aripiprazole tablets, USP, 30 mg oral tablets, packaged with 30 tablets. The label includes storage instructions to keep between 20° to 25°C with permitted excursions, dispensing instructions for pharmacists, and links to medication guides. Manufactured by Torrent Pharmaceuticals Limited.*
FDA Label Image

30mg (30mg Dahej)

30mg (30mg Dahej)
Aripiprazole Tablets, USP 30 mg oral tablets packaging label showing 30 tablets per bottle. Label includes storage instructions, NDC 13668-221-30, and manufacturer information for Torrent Pharmaceuticals Limited. The label states 'Rx only' and advises pharmacists to dispense the accompanying Medication Guide to patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.